Valuation : Nuvectra Corporation

Market Cap 1.7M 1.46M 1.38M 1.26M 2.35M 160M 2.36M 16.26M 6.31M 82.31M 6.38M 6.24M 265M P/E 2017
-1.84x
P/E 2018 -5.02x
Enterprise Value -53.46M -46M -43.28M -39.54M -73.96M -5.05B -74.16M -511M -198M -2.59B -201M -196M -8.34B EV / Sales 2017
2.58x
EV / Sales 2018 4.76x
Free-Float
96.76%
Yield 2017 *
-
Yield 2018 -
Manager TitleAgeSince
Chief Executive Officer 78 31/01/2019
Compliance Officer 51 01/01/2015
Director TitleAgeSince
Director/Board Member 67 01/03/2016
Director/Board Member 78 01/03/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+16.67% - - 268K
-0.42%-3.68%-18.43%+5.33% 187B
+1.15%+3.22%+1.42%+14.66% 120B
-1.86%+2.77%+13.07%+89.16% 63.15B
-1.31%-1.09%+22.44%+46.84% 51.75B
-1.54%-2.52%-3.41%-33.66% 50.32B
-2.02%-3.22%+8.84%-13.73% 33.17B
0.00%+3.71% - - 32.1B
-0.81%+0.74%+37.34%-16.61% 23.93B
-1.44%-4.21%-7.37%+11.97% 22.99B
Average -0.82%+1.60%+6.74%+12.99% 58.53B
Weighted average by Cap. -0.55%+0.02%-0.82%+15.45%

Financials

2017 2018
Net sales 31.84M 27.39M 25.77M 23.55M 44.05M 3.01B 44.17M 305M 118M 1.54B 120M 117M 4.97B 48.83M 42.02M 39.53M 36.11M 67.56M 4.61B 67.74M 467M 181M 2.37B 183M 179M 7.62B
Net income -44.6M -38.38M -36.11M -32.99M -61.71M -4.21B -61.87M -427M -166M -2.16B -167M -164M -6.96B -48.13M -41.42M -38.97M -35.6M -66.59M -4.54B -66.77M -460M -179M -2.33B -181M -177M -7.51B
Net Debt -1.49M -1.28M -1.21M -1.1M -2.06M -141M -2.07M -14.25M -5.53M -72.18M -5.6M -5.47M -233M -55.16M -47.46M -44.66M -40.79M -76.31M -5.21B -76.52M -528M -205M -2.67B -207M -203M -8.61B
Logo Nuvectra Corporation
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
Employees
-
  1. Stock Market
  2. Stocks
  3. NVTRQ Stock